(Reuters) – British drugmaker AstraZeneca Plc <AZN.L> said on Tuesday that its diabetes drug Farxiga was successful in reducing the risk of death by heart attack or the worsening of a type of heart failure in a late-stage study. Farxiga met the main goal of the DAPA-HF trial which tested the treatment in addition to the standard treatment in patients whose heart cannot pump enough blood and included those with or without type-2 diabetes, the company said. The results are welcome news for AstraZeneca after regulators in the United States declined to approved Farxiga for use as a supplement to insulin in adults with type-1 diabetes where insulin alone was not able to control blood sugar levels. “This (the study results) will give the drug broad applicability and is strong validation of its utility, particularly in diabetics,” Liberum analysts said. “The result will also reinforce Farxiga’s utility in diabetes at a time when oral GLP-1 might enter the market.” Farxiga belongs to a class of medicines called SGLT2 inhibitors, which control blood sugar levels by causing the kidneys to expel sugar from the body through urine. GLP-1 drugs on the other hand imitate an intestinal hormone that stimulates the production… Read full this story
- Erectile dysfunction drugs could REVERSE heart failure, study reveals
- High-protein diet linked to heart failure in older women
- FDA assigns 'breakthrough' status to an algorithm that could detect heart failure early
- Patients who are shown a picture of their clogged arteries are more likely to take action to fight heart problems, study finds
- What's Heart Failure?
- Women Born in the Spring and Summer More Likely to Die From Heart Disease, Study Suggests
- Regular cannabis use could damage heart function, study suggests
- Eating chillies cuts risk of death from heart attack: Study
- Google Publicly Debuts Its Late-Stage Growth Fund, Google Capital
- Nearly half of U.S. adults don't recognize some heart attack symptoms
AstraZeneca's Farxiga clears late-stage heart-failure study have 323 words, post on www.euronews.com at August 20, 2019. This is cached page on Business Breaking News. If you want remove this page, please contact us.